These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 10734825)

  • 41. Secretin: real therapeutic potential (response).
    Rimland B
    J Pediatr Gastroenterol Nutr; 2000 Feb; 30(2):113; author reply 113-4. PubMed ID: 10697127
    [No Abstract]   [Full Text] [Related]  

  • 42. Children with autistic spectrum disorders. II: parents are unable to distinguish secretin from placebo under double-blind conditions.
    Coplan J; Souders MC; Mulberg AE; Belchic JK; Wray J; Jawad AF; Gallagher PR; Mitchell R; Gerdes M; Levy SE
    Arch Dis Child; 2003 Aug; 88(8):737-9. PubMed ID: 12876178
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Repeated doses of porcine secretin in the treatment of autism: a randomized, placebo-controlled trial.
    Roberts W; Weaver L; Brian J; Bryson S; Emelianova S; Griffiths AM; MacKinnon B; Yim C; Wolpin J; Koren G
    Pediatrics; 2001 May; 107(5):E71. PubMed ID: 11331721
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Secretin and autism: a two-part clinical investigation.
    Chez MG; Buchanan CP; Bagan BT; Hammer MS; McCarthy KS; Ovrutskaya I; Nowinski CV; Cohen ZS
    J Autism Dev Disord; 2000 Apr; 30(2):87-94. PubMed ID: 10832772
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Secretin in a patient with treatment-resistant schizophrenia and prominent autistic features.
    Alamy SS; Jarskog LF; Sheitman BB; Lieberman JA
    Schizophr Res; 2004 Feb; 66(2-3):183-6. PubMed ID: 15061252
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Multiple doses of secretin in the treatment of autism: a controlled study.
    Sponheim E; Oftedal G; Helverschou SB
    Acta Paediatr; 2002; 91(5):540-5. PubMed ID: 12113323
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Lessons from secretin.
    Volkmar FR
    N Engl J Med; 1999 Dec; 341(24):1842-4. PubMed ID: 10588973
    [No Abstract]   [Full Text] [Related]  

  • 48. Placebo effects in autism: lessons from secretin.
    Sandler AD; Bodfish JW
    J Dev Behav Pediatr; 2000 Oct; 21(5):347-50. PubMed ID: 11064962
    [No Abstract]   [Full Text] [Related]  

  • 49. Sudden infant death syndrome and secretin treatment for autism.
    Blatt SD; Meguid V; Church CC
    Curr Opin Pediatr; 2000 Apr; 12(2):179-83. PubMed ID: 10763770
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cyproheptadine in the treatment of autistic disorder: a double-blind placebo-controlled trial.
    Akhondzadeh S; Erfani S; Mohammadi MR; Tehrani-Doost M; Amini H; Gudarzi SS; Yasamy MT
    J Clin Pharm Ther; 2004 Apr; 29(2):145-50. PubMed ID: 15068403
    [TBL] [Abstract][Full Text] [Related]  

  • 51. By any other name.
    Accardo PJ; Roseman B
    J Pediatr; 2000 May; 136(5):576-7. PubMed ID: 10802486
    [No Abstract]   [Full Text] [Related]  

  • 52. [Review of psychopharmacological treatments in adolescents and adults with autistic disorders].
    Baghdadli A; Gonnier V; Aussilloux C
    Encephale; 2002; 28(3 Pt 1):248-54. PubMed ID: 12091786
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Predicted role of secretin and oxytocin in the treatment of behavioral and developmental disorders: implications for autism.
    Welch MG; Ruggiero DA
    Int Rev Neurobiol; 2005; 71():273-315. PubMed ID: 16512355
    [No Abstract]   [Full Text] [Related]  

  • 54. Gastrointestinal microflora studies in late-onset autism.
    Finegold SM; Molitoris D; Song Y; Liu C; Vaisanen ML; Bolte E; McTeague M; Sandler R; Wexler H; Marlowe EM; Collins MD; Lawson PA; Summanen P; Baysallar M; Tomzynski TJ; Read E; Johnson E; Rolfe R; Nasir P; Shah H; Haake DA; Manning P; Kaul A
    Clin Infect Dis; 2002 Sep; 35(Suppl 1):S6-S16. PubMed ID: 12173102
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Secretin and autism: a basic morphological study about the distribution of secretin in the nervous system.
    Köves K; Kausz M; Reser D; Illyés G; Takács J; Heinzlmann A; Gyenge E; Horváth K
    Regul Pept; 2004 Dec; 123(1-3):209-16. PubMed ID: 15518914
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Spironolactone might be a desirable immunologic and hormonal intervention in autism spectrum disorders.
    Bradstreet JJ; Smith S; Granpeesheh D; El-Dahr JM; Rossignol D
    Med Hypotheses; 2007; 68(5):979-87. PubMed ID: 17150311
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Drug discovery in autism: the need for a developmental context.
    Willemsen-Swinkels SH; Buitelaar JK
    Drug Discov Today; 2004 Jun; 9(11):473. PubMed ID: 15149620
    [No Abstract]   [Full Text] [Related]  

  • 58. Is autism a G-alpha protein defect reversible with natural vitamin A?
    Megson MN
    Med Hypotheses; 2000 Jun; 54(6):979-83. PubMed ID: 10867750
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pharmacotherapy in autism: where to start?
    Acosta MT
    Drug Discov Today; 2004 Jun; 9(11):474. PubMed ID: 15149621
    [No Abstract]   [Full Text] [Related]  

  • 60. Risperidone use in the treatment of behavioral symptoms in children with autism.
    West L; Waldrop J
    Pediatr Nurs; 2006; 32(6):545-9. PubMed ID: 17256292
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.